Inspira Technologies Oxy B.H.N. Ltd. Warrant (QTEXW)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Inspira Technologies Oxy B.H.N. Ltd. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 59,160 | $22,611 | $5,916 | -$16,695 | -73.84% |
Inspira Technologies Oxy B.H.N. Ltd. Warrant (QTEXW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inspira Technologies Oxy B.H.N. Ltd. Warrant ever had a stock split?
Inspira Technologies Oxy B.H.N. Ltd. Warrant Profile
| Household Durables Industry | Consumer Discretionary Sector | Dagi Shahar Ben-Noon CEO | NASDAQ (NMS) Exchange | M53637118 CUSIP |
| IL Country | 34 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company focused on innovating respiratory support technology aimed at providing alternatives to invasive mechanical ventilation (MV) for patients suffering from respiratory failure. The company was originally founded as Insense Medical Ltd. and underwent a name change to its current identity in July 2020. Incorporated in 2018, Inspira Technologies is headquartered in Ra'annana, Israel, where it actively engages in the research, development, manufacturing, and marketing of its groundbreaking products. With a strong emphasis on addressing critical respiratory needs, the company continues to advance its technology to improve patient outcomes.
Products and Services
- Augmented Respiration Technology System (ART)
The flagship product of Inspira Technologies, the Augmented Respiration Technology System (ART), is designed as a revolutionary respiratory support system that provides a non-invasive alternative to traditional mechanical ventilation. The ART utilizes a minimally invasive, portable dual lumen cannula that is inserted into the jugular vein to facilitate extra-corporeal direct blood oxygenation. This innovative approach is aimed at significantly elevating and stabilizing declining oxygen saturation levels, thus enhancing the treatment of patients with respiratory failure.
